Logo image of RLYB

RALLYBIO CORP (RLYB) Stock Price, Quote, News and Overview

NASDAQ:RLYB - Nasdaq - US75120L1008 - Common Stock - Currency: USD

0.3293  0 (-0.21%)

After market: 0.3201 -0.01 (-2.79%)

RLYB Quote, Performance and Key Statistics

RALLYBIO CORP

NASDAQ:RLYB (5/23/2025, 8:53:18 PM)

After market: 0.3201 -0.01 (-2.79%)

0.3293

0 (-0.21%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.73
52 Week Low0.22
Market Cap13.70M
Shares41.61M
Float36.85M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO07-29 2021-07-29


RLYB short term performance overview.The bars show the price performance of RLYB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

RLYB long term performance overview.The bars show the price performance of RLYB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of RLYB is 0.3293 USD. In the past month the price increased by 8.57%. In the past year, price decreased by -78.89%.

RALLYBIO CORP / RLYB Daily stock chart

RLYB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.84 324.18B
AMGN AMGEN INC 13.09 146.06B
GILD GILEAD SCIENCES INC 13.87 133.68B
VRTX VERTEX PHARMACEUTICALS INC N/A 112.09B
REGN REGENERON PHARMACEUTICALS 13.28 63.52B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.72B
ARGX ARGENX SE - ADR 100.1 35.88B
ONC BEIGENE LTD-ADR 6 26.02B
BNTX BIONTECH SE-ADR N/A 23.72B
NTRA NATERA INC N/A 20.84B
SMMT SUMMIT THERAPEUTICS INC N/A 19.20B
BIIB BIOGEN INC 7.95 18.43B

About RLYB

Company Profile

RLYB logo image Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut and currently employs 25 full-time employees. The company went IPO on 2021-07-29. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The company has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, is a C5-targeted Affibody molecule conjugated to polyethylene glycol; RLYB332, is a preclinical antibody designed to inhibit MTP-2, and REV102 Program, is a small molecule inhibitor of ectonucleotide pyrophosphatase/ phosphodiesterase 1(ENPP1).

Company Info

RALLYBIO CORP

234 Church Street, Suite 1020

New Haven CONNECTICUT US

CEO: Martin W. Mackay

Employees: 25

RLYB Company Website

RLYB Investor Relations

Phone: 12038593820

RALLYBIO CORP / RLYB FAQ

What is the stock price of RALLYBIO CORP today?

The current stock price of RLYB is 0.3293 USD. The price decreased by -0.21% in the last trading session.


What is the ticker symbol for RALLYBIO CORP stock?

The exchange symbol of RALLYBIO CORP is RLYB and it is listed on the Nasdaq exchange.


On which exchange is RLYB stock listed?

RLYB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for RALLYBIO CORP stock?

11 analysts have analysed RLYB and the average price target is 1.02 USD. This implies a price increase of 209.75% is expected in the next year compared to the current price of 0.3293. Check the RALLYBIO CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is RALLYBIO CORP worth?

RALLYBIO CORP (RLYB) has a market capitalization of 13.70M USD. This makes RLYB a Nano Cap stock.


How many employees does RALLYBIO CORP have?

RALLYBIO CORP (RLYB) currently has 25 employees.


What are the support and resistance levels for RALLYBIO CORP (RLYB) stock?

RALLYBIO CORP (RLYB) has a support level at 0.29 and a resistance level at 0.43. Check the full technical report for a detailed analysis of RLYB support and resistance levels.


Is RALLYBIO CORP (RLYB) expected to grow?

The Revenue of RALLYBIO CORP (RLYB) is expected to decline by -89.52% in the next year. Check the estimates tab for more information on the RLYB EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy RALLYBIO CORP (RLYB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does RALLYBIO CORP (RLYB) stock pay dividends?

RLYB does not pay a dividend.


What is the Price/Earnings (PE) ratio of RALLYBIO CORP (RLYB)?

RALLYBIO CORP (RLYB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.09).


What is the Short Interest ratio of RALLYBIO CORP (RLYB) stock?

The outstanding short interest for RALLYBIO CORP (RLYB) is 0.99% of its float. Check the ownership tab for more information on the RLYB short interest.


RLYB Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to RLYB. When comparing the yearly performance of all stocks, RLYB is a bad performer in the overall market: 97.78% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

RLYB Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to RLYB. RLYB has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RLYB Financial Highlights

Over the last trailing twelve months RLYB reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS increased by 42.02% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -84.83%
ROE -93.71%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%55.32%
Sales Q2Q%N/A
EPS 1Y (TTM)42.02%
Revenue 1Y (TTM)N/A

RLYB Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 75% to RLYB. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 36.53% and a revenue growth -89.52% for RLYB


Ownership
Inst Owners69.98%
Ins Owners2.32%
Short Float %0.99%
Short Ratio3.21
Analysts
Analysts74.55
Price Target1.02 (209.75%)
EPS Next Y36.53%
Revenue Next Year-89.52%